1、novotech-2025Hepatitis B-Global Clinical Trial LandscapeTrials advance treatment through RNAi,gene therapies,therapeutic vaccines,and epigenetic modifiers some of which are aimed at achieving complete cureThe U.S.and China led Hepatitis B venture funding,with significant contributions from the UK,Si

2、ngapore,France,and TaiwanCountries like Mainland China,Hong Kong,South Korea,Taiwan,and the United States,emerged as top locations for conducting trialsHepatitis B trials utilize biomarkers for disease management,with emerging markers like HBV RNA and HBcrAg enhancing diagnostics and treatmentHEPATI

3、TIS B TRIAL CONTRIBUTIONSHepatitis B is a highly infectious liver disease that can lead to chronic infection,cirrhosis,and cancerThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any m

4、eans,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its con

5、tent and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communication

6、snovotech-HEPATITIS B GLOBAL CLINICAL TRIAL LANDSCAPE(2025)CHRONIC HEPATITIS B CASES2022254MGLOBAL DEATHS1.1M30%NORTH AMERICA&EUROPE40%ASIA-PACIFICROW5%#DYK Did youknow?The African region carries a substantial Hepatitis B burden,with South Africa among the most afected countriesIn the Asia-Pacific,C